Fig. 4

Shared and special molecular alterations in entire and early stage LUAD samples. A Comparison of fold-changes in early stage or entire LUAD samples to non-tumor samples. Red dots: proteins up-regulated (fold of change > 2, p < 0.05) in both early stage or entire LUAD groups. Blue dots: proteins down-regulated (fold of change < 1/2, p < 0.05) in both early stage or entire LUAD groups. Orange dots: proteins up-regulated (fold of change > 2, p < 0.05) in only early stage group. Pink dots: proteins up-regulated (fold of change > 2, p < 0.05) in only entire LUAD group. Grey dots: proteins without significant change (p > 0.05) in both early stage or entire LUAD groups. B KEGG pathways enriched in shared up-regulated proteins. C The log-rank p values and fold of changes of the shared up-regulated proteins. Proteins belonging to clinical successful or potential drug targets were labeled with gene names. D KEGG pathways enriched in Stage I unique up-regulated proteins. E Distributions of the expression level of four ‘Stage I unique up-regulated proteins’ belonging to mitophagy pathway in non-tumor, early stage and middle and late stage tumor groups. (*p < 0.05. **p < 0.01. ***p < 0.001.). F Kaplan–Meier curve of overall survival in samples with high expression (red line) and low expression (blue line) of TFEB